NCT Number: NCT05823402
Phase: NA
Trial Summary: The SPECTacular study will enroll patients who are already undergoing a FDA approved PSMA-targeted Radioligand treatment cycle. During each treatment cycle, patients will receive 5 additional SPECT/CT – clinicaltrials.gov for more
Clinicaltrials.gov
Trial Sponsor(s): BAMF Health
Acronym: SPECTacular
Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives